• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, April 27, 2018


Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

This week, The American Journal of Managed Care® (AJMC®) headed to Boston, Massachusetts, to cover the Academy of Managed Care Pharmacy’s Managed Care & Specialty Pharmacy Annual Meeting. AJMC®’s coverage of the conference was highlighted in the National Pharmaceutical Council’s Wednesday CER Daily Newsfeed, which included the article “Who Decides What Value Looks Like in US Healthcare?” The article covered a session focused on visions of a value-based healthcare system.

Tuesday’s CER Daily Newsfeed featured an AJMC® article, “Report Outlines Roadmap for Continued Support of Value-Based Payment Models,” which covered a report that suggests ways that policy makers can support and advance value-based payment models so payment innovations can catch up to healthcare delivery innovations.

Kaiser Family Foundation's Thursday Health Policy Report included an article from AJMC® on global funding for HIV/AIDS. The article, "Long-Term Analysis Highlights Half Trillion Dollars Spent on HIV/AIDS," reported on an alaysis that found between 2000 and 2015, $562.6 billion was spent on HIV/AIDS, with most spending occurring in high-income and upper-middle-income countries and out-of-pocket spending accounting for less than 10%.

The Heritage Foundation’s article on direct primary care included a study published in AJMC® that assessed the impact of the MDVIP model of personalized preventive care. The study, “Personalized Preventive Care Leads to Significant Reductions in Hospital Utilizations,” conducted an analysis comparing MDVIP members and nonmembers and found that MDVIP members were admitted 97%, 95%, and 91% less frequently for myocardial infarction, congestive heart failure, and pneumonia, respectively. GoSkagit also highlighted the study, which found that the decreases in hospital visits resulted in a savings of $2551 per patient in 2010.

Related Videos
Video 12 - "Harnessing Indication-Specific Data on Biosimilars"
Video 11 - "An Overview of Biosimilar Extrapolation During FDA Approval"
Video 3 - "Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape"
Video 2 - "Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023"
Video 1 - "Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers"
Related Content
© 2023 MJH Life Sciences
All rights reserved.